Otrexup

Drug - Otrexup™ (methotrexate for subcutaneous injection) [Antares Pharma, Inc.]

June 2014

Therapeutic area - Rheumatoid arthritis; polyarticular juvenile idiopathic arthritis; psoriasis

Approval criteria

Approval will only be granted for diagnoses of rheumatoid arthritis; polyarticular juvenile idiopathic arthritis (pJIA); severe, disabling psoriasis.

Rheumatoid Arthritis, pJIA approval criteria

• Patient must have a diagnosis of rheumatoid arthritis or pJIA AND
• Patient cannot swallow a tablet whole AND
• Patient is not taking any other tablet whole by mouth OR
• Prescriber provides a compelling reason why patient cannot take generically available methotrexate by mouth or injection

Psoriasis approval criteria

• Patient must have a diagnosis of psoriasis AND
• Patient has tried and failed topical therapy AND
• Patient cannot swallow a tablet whole AND
• Patient is not taking any other tablet whole by mouth OR
• Prescriber provides a compelling reason why patient cannot take generically available methotrexate by mouth or injection

Quantity limit

1.6 ml per 34 days (all strengths)

Background information

Otrexup™ will only be authorized for approved FDA indications.

Questions?

MHCP Provider Call Center 651-431-2700 or 800-366-5411